Your browser is no longer supported. Please, upgrade your browser.
NBRV Nabriva Therapeutics plc daily Stock Chart
NBRV [NASD]
Nabriva Therapeutics plc
Index- P/E- EPS (ttm)-1.31 Insider Own1.50% Shs Outstand157.55M Perf Week-3.30%
Market Cap115.78M Forward P/E- EPS next Y-0.41 Insider Trans0.00% Shs Float141.80M Perf Month6.31%
Income-85.80M PEG- EPS next Q-0.12 Inst Own24.10% Short Float3.76% Perf Quarter20.57%
Sales8.60M P/S13.46 EPS this Y50.60% Inst Trans3.79% Short Ratio0.54 Perf Half Y-44.74%
Book/sh0.21 P/B3.52 EPS next Y32.30% ROA- Target Price- Perf Year-67.77%
Cash/sh0.32 P/C2.32 EPS next 5Y- ROE- 52W Range0.49 - 2.77 Perf YTD-44.33%
Dividend- P/FCF- EPS past 5Y31.10% ROI-105.00% 52W High-73.47% Beta2.41
Dividend %- Quick Ratio5.20 Sales past 5Y31.60% Gross Margin99.10% 52W Low51.53% ATR0.06
Employees162 Current Ratio5.70 Sales Q/Q0.00% Oper. Margin- RSI (14)43.17 Volatility5.47% 8.43%
OptionableYes Debt/Eq0.17 EPS Q/Q- Profit Margin- Rel Volume0.40 Prev Close0.81
ShortableYes LT Debt/Eq0.17 EarningsAug 06 AMC Payout- Avg Volume9.79M Price0.73
Recom2.80 SMA20-6.53% SMA50-6.49% SMA200-35.19% Volume3,909,348 Change-9.27%
Mar-19-20Downgrade Wedbush Outperform → Neutral
May-02-19Upgrade Gabelli & Co Sell → Hold
May-02-19Reiterated H.C. Wainwright Buy $9 → $7
Sep-07-18Resumed Morgan Stanley Overweight
Mar-21-18Initiated BofA/Merrill Buy $10
Jan-17-18Initiated Morgan Stanley Overweight
Nov-01-17Reiterated H.C. Wainwright Buy $18 → $20
Aug-25-17Initiated SunTrust Buy $20
Feb-01-17Reiterated Wedbush Outperform $13
Oct-27-16Resumed Leerink Partners Outperform $14
Sep-08-16Initiated H.C. Wainwright Buy $16
Jan-27-16Initiated Gabelli & Co Buy $14
Nov-12-15Reiterated RBC Capital Mkts Outperform $21 → $22
Oct-13-15Initiated Wedbush Outperform
Oct-13-15Initiated RBC Capital Mkts Outperform $21
Oct-13-15Initiated Leerink Partners Outperform $19
Oct-12-15Initiated Needham Buy $15
Aug-06-20 04:01PM  
Aug-03-20 07:00AM  
Jul-30-20 04:01PM  
Jul-29-20 10:21AM  
Jul-28-20 10:02AM  
Jul-23-20 07:00AM  
Jul-17-20 11:12AM  
07:41AM  
Jul-16-20 04:04PM  
12:00PM  
Jul-15-20 04:01PM  
Jun-23-20 09:12PM  
Jun-22-20 03:23PM  
Jun-19-20 08:52PM  
07:41AM  
Jun-10-20 08:39AM  
Jun-08-20 07:19AM  
Jun-01-20 04:00PM  
08:40AM  
May-29-20 07:31PM  
08:00AM  
May-27-20 04:01PM  
May-18-20 08:00AM  
May-11-20 04:01PM  
07:00AM  
May-08-20 07:00AM  
May-07-20 08:32AM  
May-05-20 07:00AM  
Apr-14-20 08:59AM  
Apr-09-20 07:00AM  
Apr-08-20 07:00AM  
Apr-02-20 10:08AM  
Mar-17-20 09:33AM  
Mar-12-20 04:01PM  
02:30PM  
Mar-10-20 04:01PM  
Mar-05-20 08:21AM  
Mar-03-20 09:38AM  
Mar-02-20 04:01PM  
Feb-05-20 04:01PM  
Jan-22-20 08:24AM  
Jan-09-20 08:39AM  
Jan-08-20 04:01PM  
Dec-20-19 03:06PM  
08:37AM  
06:44AM  
06:00AM  
Dec-19-19 09:38PM  
Dec-10-19 10:31AM  
Dec-02-19 04:01PM  
Nov-23-19 06:55PM  
Nov-21-19 04:01PM  
Nov-20-19 07:49PM  
Nov-18-19 07:00AM  
Nov-12-19 04:01PM  
Nov-01-19 04:01PM  
Oct-31-19 07:00AM  
Oct-15-19 07:00AM  
Oct-11-19 06:32PM  
Oct-01-19 04:01PM  
10:07AM  
Sep-27-19 12:15PM  
Sep-26-19 04:01PM  
Sep-18-19 07:00AM  
Sep-11-19 09:32AM  
Sep-09-19 07:00AM  
Sep-06-19 04:01PM  
07:00AM  
Aug-29-19 09:15AM  
Aug-28-19 07:00AM  
Aug-21-19 12:15PM  
11:00AM  
Aug-20-19 04:47PM  
02:40PM  
12:42PM  
08:36AM  
08:33AM  
07:33AM  
Aug-19-19 08:33PM  
05:55PM  
03:45PM  
03:41PM  
03:10PM  
Aug-17-19 01:46PM  
Aug-16-19 11:17AM  
07:33AM  
07:00AM  
Aug-14-19 01:02PM  
Aug-08-19 07:00AM  
Aug-06-19 07:00AM  
Jul-18-19 02:36PM  
Jul-17-19 04:02PM  
Jul-08-19 01:35PM  
11:37AM  
10:23AM  
10:00AM  
Jul-05-19 07:30PM  
03:00PM  
10:47AM  
10:28AM  
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; for the treatment of acute bacterial skin and skin structure infection; and that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, osteomyelitis, and prosthetic joint infections. It is also developing CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Broom Colin MDDirectorAug 30Buy2.0310,17720,668208,750Sep 03 04:04 PM
Schroeder Theodore RChief Executive OfficerAug 27Buy1.7950,00089,500117,489Aug 28 04:01 PM
Lavino Francesco MariaChief Commercial OfficerAug 22Buy2.044,8009,78015,972Aug 26 09:49 PM